44 Hartwell Avenue
About Homology Medicines
Homology Medicines is based on groundbreaking science that harnesses the naturally occurring process of homologous recombination. This non-nuclease-based approach offers clear advantages in its precision, efficiency and on-target in vivo editing of genetic mutations. Homology obtained an exclusive worldwide license to this technology platform, which is based on the pioneering research of Saswati Chatterjee, Ph.D., Professor of Virology at the Beckman Research Institute at the City of Hope in California, member of the Recombinant DNA Advisory Committee (RAC) to the Office of the Director, National Institutes of Health (NIH) and former charter member of the Therapeutic Approaches to Genetic Diseases Study Section of the NIH. Dr. Chatterjee and her team led the first adeno-associated virus (AAV) vector-mediated gene transfer studies into human hematopoietic stem cells and subsequently identified and isolated a series of naturally-occurring AAVs from human CD34+ cells.
Founder: Saswati Chatterjee
President and CEO: Arthur Tzianabos, Ph.D.
COO: Sam Rasty, Ph.D.
CSO: Albert Seymour, Ph.D.
Please click here for Homology job opportunities.
26 articles with Homology Medicines
The annual meeting of the American Society of Gene & Cell Therapy (ASGCT) was held in Washington, DC this week, with literally hundreds of abstracts and presentations. Here’s a look at some of the highlights.
The last year has been a busy one for Bedford, Mass.-based Homology Medicines. Albert Seymour, Homology’s chief science officer, took time out to talk to BioSpace about the company and where it’s headed.
Homology Medicines Announces FDA Clearance of Investigational New Drug Application for HMI-102 Gene Therapy Candidate for PKU
Phase 1/2 pheNIX Trial Would Represent First PKU Gene Therapy to Enter the Clinic
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
Most of the IPOs that occurred in the Bay State have been well-documented by BioSpace. But, with a new calendar year upon us, it’s a good idea to look back at a banner year of capitalization that may not repeat when January rolls around. With the turn of the year only days away, BioSpace takes a ...
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
Homology Medicines, Inc. announced today that Homology will present at the following conferences
Company on Track to Begin and Report Initial Data from Phase 1/2 Gene Therapy Program and Advance Gene Editing Platform into IND-Enabling Studies in PKU in 2019
Akouos, based in Boston, announced a Series A financing worth $50 million. The round was led by seed investors 5AM Ventures and New Enterprise Associates (NEA).
Homology Medicines Announces Peer-Reviewed Publication Demonstrating Efficient and Precise In Vivo Gene Editing Capabilities of Nuclease-Free Technology Platform
Homology Medicines, Inc. announced a peer-reviewed publication demonstrating that Homology's technology induces efficient and precise in vivo gene editing.
Homology Medicines, Inc. announced that it will present data from its phenylketonuria (PKU) gene therapy program and will participate on a panel on emerging therapies at the National PKU Alliance (NPKUA) Conference July 5-8, 2018 at the Hilton Downtown Atlanta.
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
Homology Medicines Presents Data from PKU Gene Therapy Program Demonstrating Long-Term Durability of Treatment in IND-Enabling Studies
Presentations Also Demonstrate Phenotypic Correction of PKU Model with Homology's Nuclease-Free Gene Editing Approach and Ability of Platform to Target Ophthalmic Disorders
Despite raised awareness over the past few years, the gender diversity gap in the boardrooms of Fortune 1000 companies has remained at slightly less than 20 percent, as of 2017. There is evidence though that shows companies with more diversity at the highest levels see a higher return on investme...
Homology Medicines has raised $144 million in an initial public offering of stock.
Homology Medicines, Inc. announced the pricing of its initial public offering of 9,000,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions.
Things are looking up for Massachusetts-based Homology Medicines.
Mr. Patterson is a biotech industry leader with more than 24 years of experience in research, development and commercialization of innovative treatments for rare diseases.
Homology Medicines and Novartis Enter Collaboration to Develop New Treatments Using Homology's Proprietary Gene Editing Technology
Under the terms of the agreement, Novartis made an upfront payment to and an equity investment in Homology.